Stories - Eye on Innovation Archives - Insights

Precision in the pancreas: A new genetic test transforms hereditary pancreatitis diagnosis and care

jgilligan1 — Tue, 24 Jun 2025 13:00:00 +0000

Mayo Clinic Laboratories’ newly expanded Hereditary Pancreatitis Gene Panel is transforming how clinicians diagnose and manage a complex, often elusive disease. Developed through close collaboration between lab scientists, genetic counselors, and clinicians, the test uses a whole exome sequencing backbone to analyze nine carefully selected genes with strong clinical relevance. This focused approach avoids ambiguous results while empowering early diagnosis, cancer risk assessment, and family testing. Built on a whole exome backbone with reflex capabilities, the panel represents a major step forward in precision medicine — offering clarity for patients and providers, and a platform for future genomic innovation.

The post Precision in the pancreas: A new genetic test transforms hereditary pancreatitis diagnosis and care appeared first on Insights.

Neurofilament light chain test helps in diagnosis, treatment, and prognosis of ALS and MS

Chris Bahnsen — Mon, 14 Apr 2025 13:00:00 +0000

By using a test that measures neurofilament light chain (Nfl) proteins in blood, clinicians can better diagnose devastating diseases like ALS and MS, help predict disease progression, and better assess efficacy of existing drugs and trial therapies.

The post Neurofilament light chain test helps in diagnosis, treatment, and prognosis of ALS and MS appeared first on Insights.

New test distinguishes between prion disease and other causes of rapidly progressive dementia

Chris Bahnsen — Mon, 03 Feb 2025 14:00:00 +0000

Performed on cerebrospinal fluid, Mayo Clinic’s RT-QuIC prion test can distinguish prion disease from other types of rapidly progressive dementias to enhance patient care.

The post New test distinguishes between prion disease and other causes of rapidly progressive dementia appeared first on Insights.

Driving change in women’s health testing through pioneering research and novel testing strategies

Robin Huiras-Carlson — Mon, 02 Dec 2024 14:00:00 +0000

New diagnostic tests specifically for conditions that predominantly or only affect women, such as autoimmune diseases and gynecological cancers, are empowering female patients and their physicians to make informed decisions.

The post Driving change in women’s health testing through pioneering research and novel testing strategies appeared first on Insights.

Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing

Barbara J. Toman — Mon, 21 Oct 2024 13:15:00 +0000

Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.

The post Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing appeared first on Insights.

Innovative bile acid malabsorption panel transforms gastrointestinal care

Nicole Holman — Mon, 12 Aug 2024 13:00:00 +0000

Mayo Clinic Laboratories has introduced a revolutionary diagnostic test for bile acid malabsorption, a significant contributor to chronic diarrhea. Developed by Dr. Michael Camilleri and Dr. Leslie Donato, this new bile acid malabsorption panel simplifies diagnosis and improves patient care by eliminating the need for special diets or prolonged stool collection. The test's effectiveness has been validated internationally, offering new treatment avenues for patients. Discover how this innovative test is transforming clinical practice and enhancing patient outcomes.

The post Innovative bile acid malabsorption panel transforms gastrointestinal care appeared first on Insights.

Widening the net to capture elusive pathogens

Barbara J. Toman — Mon, 03 Jun 2024 13:00:00 +0000

Central nervous system infections, such as meningitis and encephalitis, can be devastating for affected patients. While specific treatments are available for some of these infections, it first requires identifying the precise cause of infection. To meet that need, Mayo Clinic Laboratories has developed a metagenomics assay that can identify more than 1,000 pathogenic organisms in cerebrospinal fluid. The innovative assay, which uses an approach known as shotgun metagenomic sequencing, is one of the only such tests currently available.

The post Widening the net to capture elusive pathogens appeared first on Insights.

A new comprehensive genetic panel redefines Parkinson’s disease diagnosis

Nicole Holman — Wed, 10 Apr 2024 13:00:00 +0000

Mayo Clinic Laboratories introduces the Inherited Parkinson’s Disease Gene Panel (Mayo ID: PARDP), a collaborative breakthrough poised to transform Parkinson’s disease diagnosis and treatment. Led by Rodolfo Savica, M.D., Ph.D., and Zhiyv (Neal) Niu, Ph.D., this comprehensive test offers unparalleled insights into Parkinson’s genetics, unveiling novel gene associations and enhancing diagnostic precision through next-generation sequencing. The panel’s capabilities include detecting subtle genetic variations and identifying familial patterns, promising personalized medicine advancements.

The post A new comprehensive genetic panel redefines Parkinson’s disease diagnosis appeared first on Insights.

A comprehensive test menu explores genome for druggable targets to treat gastrointestinal cancers

Chris Bahnsen — Wed, 13 Mar 2024 13:00:00 +0000

Since 1992, cases of colorectal cancer have been on a slow decline, yet 52,550 people died from it in 2023. At Mayo Clinic, a cutting-edge menu of both germline (inherited genetic alterations) and somatic (tumors due to non-inherited genetic alterations) testing are two critical tools helping to improve targeted treatments for colorectal and other common gastrointestinal cancers.

The post A comprehensive test menu explores genome for druggable targets to treat gastrointestinal cancers appeared first on Insights.

Pushing the envelope on personalized medicine

Robin Huiras-Carlson — Wed, 21 Feb 2024 14:00:00 +0000

Recognizing the powerful role genes can play in diagnosing illness and guiding treatment, the Division of Laboratory Genetics and Genomics at Mayo Clinic spearheaded a testing expansion, implementing and upgrading more than 60 advanced sequencing and biochemical assays in 2023 and planning for even more this year.

The post Pushing the envelope on personalized medicine appeared first on Insights.